[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349025-105":59,"doc-detail-349025-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","reframing-disease-burden-validation-of-daly-per-case-as-a-per-diagnosis-severity-metric","Reframing disease burden: validation of DALY-per-case as a per-diagnosis severity metric","","Population-weighted health metrics such as incidence, mortality, DALYs, and the mortality-to-incidence ratio (MIR) can hide per-case severity for less prevalent but high-impact conditions. This study proposes DALY per case, defined as total DALYs divided by incident cases, to estimate healthy life-years lost per new diagnosis by integrating YLL and YLD. Using GBD 2021, results are validated across 34 cancers and extended to non-cancer conditions, enabling prevalence-independent severity comparisons.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reframing-disease-burden-validation-of-daly-per-case-as-a-per-diagnosis-severity-metric/349025/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reframing-disease-burden-validation-of-daly-per-case-as-a-per-diagnosis-severity-metric/349025.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does DALY-per-case measure in this study?","Question",{"text":112,"@type":113},"DALY-per-case is total DALYs divided by incident cases, representing healthy life-years lost per new diagnosis by combining YLL and YLD.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is DALY-per-case validated and tested for generalizability?",{"text":117,"@type":113},"Validation is performed on 34 cancers using GBD 2021, and generalizability is tested in five non-cancer conditions: type 2-diabetes, tuberculosis, HIV/AIDS, ischemic heart disease, and Alzheimer’s.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship does DALY-per-case show with survival and the mortality-to-incidence ratio?",{"text":121,"@type":113},"DALY-per-case correlates inversely with 5-year survival (r=-0.72) and positively with MIR (r=0.75), supporting its usefulness as an individual-severity metric.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349025,1790161831,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Freihat Population Health Metrics (2026) 24:28 Population Health Metrics  \n[https://doi.org/10.1186/s12963-026-00469-2](https://doi.org/10.1186/s12963-026-00469-2)  \nRESEARCH Open Access  \nReframing disease burden: validation of DALY- per-case as a per-diagnosis severity metric  \nOmar Freihat 1*  \nAbstract  \nBackground Population-weighted metrics (incidence, mortality, disability-adjusted life years (DALYs), mortality to incidence ratio (MIR) can obscure per-case severity for less prevalent but high-impact conditions. This paper introduces DALY per case, total DALYs divided by incident cases, as a standardized estimate of healthy life-years lost per new diagnosis, integrating years of life lost (YLL) and years lived with disability (YLD) . Validated using cancers and applied across diverse diseases, the metric enables prevalence-independent severity comparisons.  \nMethods Using GBD 2021, we computed DALY per case across diseases (all ages, both sexes), validated on 34 cancers, and tested generalizability in five non-cancer conditions (type 2-diabetes, tuberculosis, HIV/AIDS, ischemic heart disease, Alzheimer’s) . We compared rankings with incidence, mortality, and total DALYs. A 2-Dimensional framework plotted total DALYs (population burden) vs. DALY-per-case (individual severity) with median-based quadrant thresholds. Uncertainty intervals (UIs) were propagated per GBD conventions; stability was assessed via relative UI width, band-crossing, and sensitivity analyses. Construct/convergent validity used correlations with 5-year survival Surveillance, Epidemiology, and End Results Program (SEER) and MIR; full and reduced regressions tested independence.  \nResults High-severity cancers included malignant bone tumours (27 .6 DALYs/case), neuroblastoma (26 . 3), and brain/CNS (24 . 9), contrasting with population-dominant burdens such as lung (46 .5 million DALYs; 20 .4/case) and colorectal (24 .4 million; 11. 1/case) . Relative uncertainty spanned 27%(breast) to 96%(Hodgkin lymphoma); rankings were largely preserved despite wide UIs in select sites. DALY-per-case correlated inversely with 5-year survival (r=-0 . 72, p \u003C 0. 001) and positively with MIR (r = 0 . 75, p \u003C 0. 001) . In regression, MIR showed the strongest effect (β = 0 . 52, p = 0 . 06); survival lost significance when MIR was included, indicating shared but non-redundant variance.  \nConclusions DALY-per-case provides a disease-agnostic toolkit, including a 2Dimensional burden-severity framework and validation against existing indicators, to quantify per-diagnosis severity and inform policy across communicable and non-communicable diseases.  \nKeywords Disability-adjusted life years, Per-incident burden, Comparative epidemiology, Mortality-to-incidence ratio, Severity stratification, Burden decomposition, Global health metrics  \n*Correspondence:  \nOmar Freihat  \n[Freihat.omar@yahoo.com](Freihat.omar@yahoo.com); [Omar.freihat@adu.ac.ae](Omar.freihat@adu.ac.ae)  \n1Department of environmental and public health, college of health science, Abu Dhabi University, Abu Dhabi 59911, UAE  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain","cbCaiuooEgzslDDv","https://ap.wps.com/l/cbCaiuooEgzslDDv","pdf",1380962,12,"English","# Abstract\n# Introduction\n## Limitations of existing population-weighted metrics\n## Rationale for per-diagnosis severity\n## Study aim and DALY-per-case definition\n# Methods\n## Data source and computation\n## Validation and generalizability\n## 2D burden-severity framework and uncertainty propagation\n## Validity testing using survival and MIR\n# Results\n## High- vs low-severity cancers and examples\n## Uncertainty range and ranking stability\n## Correlation with survival and MIR\n## Regression findings\n# Conclusions","[{\"question\":\"What does DALY-per-case measure in this study?\",\"answer\":\"DALY-per-case is total DALYs divided by incident cases, representing healthy life-years lost per new diagnosis by combining YLL and YLD.\"},{\"question\":\"How is DALY-per-case validated and tested for generalizability?\",\"answer\":\"Validation is performed on 34 cancers using GBD 2021, and generalizability is tested in five non-cancer conditions: type 2-diabetes, tuberculosis, HIV/AIDS, ischemic heart disease, and Alzheimer’s.\"},{\"question\":\"What relationship does DALY-per-case show with survival and the mortality-to-incidence ratio?\",\"answer\":\"DALY-per-case correlates inversely with 5-year survival (r=-0.72) and positively with MIR (r=0.75), supporting its usefulness as an individual-severity metric.\"}]","Reframing disease burden: validation of DALY-per-case as a per-diagnosis severity metric | PDF",1790081248,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7d13040fc2084fc6c36d2642b908cd1.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/990ecae29023b38b2bb9c4c1e1c2d104.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac83a173b8709831835d674ffac487f4.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83a24299d4fbb192c8d99235ee382179.webp",980,1306]